导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.28% | 3288/4773 |
| 近一周 | -2.01% | 3953/5467 |
| 近一月 | -2.93% | 1076/5421 |
| 近一季 | -1.68% | 1184/5238 |
| 近半年 | -2.27% | 2273/4931 |
| 近一年 | -1.09% | 2792/4400 |
| 近两年 | 35.62% | 2078/2954 |
| 近三年 | 22.38% | 1378/2253 |
| 成立以来 | 39.76% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.63% 4168/4961 |
6.69% 2802/5312 |
- - |
- - |
| 2025 | 15.85% 2508/4813 |
-0.60% 2318/3635 |
2.83% 1326/4076 |
11.08% 3204/4524 |
2.04% 1098/4813 |
| 2024 | 18.85% 573/3463 |
3.61% 536/2808 |
-0.14% 692/3014 |
17.26% 1221/3129 |
-2.03% 1933/3463 |
| 2023 | -9.23% 1134/2656 |
0.89% 1677/2280 |
-4.82% 1295/2385 |
1.56% 299/2515 |
-6.92% 1977/2655 |
| 2022 | -16.85% 522/2207 |
-11.51% 521/1919 |
6.83% 595/2016 |
-13.32% 879/2113 |
1.47% 1252/2208 |
| 2021 | -6.29% 1003/1822 |
-2.30% 613/1255 |
0.64% 1088/1330 |
-6.98% 1011/1466 |
2.46% 591/1822 |
| 2020 | 29.42% 540/1250 |
-10.51% 786/1028 |
12.39% 686/1067 |
14.05% 301/1164 |
12.82% 428/1184 |
| 2019 | 40.88% 242/1092 |
23.74% 542/754 |
4.56% 24/804 |
1.97% 340/850 |
6.78% 550/918 |
| 2018 | -19.53% 170/834 |
- - |
- - |
- - |
-12.15% 411/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4796 | 32.41% |
| 港股通药 | 0.9109 | 32.37% |
| 港股通医疗ETF工银 | 0.9798 | 32.23% |
| 港股通医疗ETF华宝 | 0.9918 | 32.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8599 | 32.08% |
| 港股医疗 | 0.9703 | 31.90% |
| 港医疗 | 0.9212 | 31.83% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.9074 | 30.77% |
| 永赢中证港股通医疗主题ETF发起联接C | 0.9055 | 30.72% |
| 嘉实中证港股通创新药指数发起式A | 0.8665 | 30.57% |
| 建信上证50ETF VS. 长安沪深300非周期A(740101) |